CERS — Cerus Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall CapNeutral
- $348.47m
- $327.54m
- $188.32m
- 56
- 28
- 36
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.04 | ||
| Price to Tang. Book | 6.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.13% | ||
| Return on Equity | -66.81% | ||
| Operating Margin | -20.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 76.05 | 93.77 | 114.25 | 159.52 | 188.31 | 172.56 | 200.74 | 29.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.
Directors
- Daniel Swisher NEC (58)
- William Greenman CEO (54)
- Kevin Green CFO (49)
- Vivek Jayaraman COO (46)
- Carol Moore SVP (71)
- Laurence Corash CSO (77)
- Chrystal Menard GCN (50)
- Richard Benjamin OTH (61)
- Ann Lucena DRC
- Eric Bjerkholt IND (61)
- Timothy Moore IND (59)
- Jami Nachtsheim IND (62)
- Gail Schulze IND (69)
- Frank Witney IND (67)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- July 31st, 1996
- Public Since
- January 31st, 1997
- No. of Shareholders
- 119
- No. of Employees
- 309
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 180,552,190
- Address
- 2550 STANWELL DRIVE, CONCORD, 94520
- Web
- https://www.cerus.com/
- Phone
- +1 9252886000
- Auditors
- Ernst & Young LLP
Upcoming Events for CERS
Q2 2023 Cerus Corp Earnings Release
Q3 2023 Cerus Corp Earnings Release
Similar to CERS
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
What is the Cerus share price?
As of Today at 13:04 UTC, shares in Cerus are trading at $1.96. This share price information is delayed by 15 minutes.
How has the Cerus share price performed this year?
Shares in Cerus last closed at $1.96 and the price had moved by -59.5% over the past 365 days. In terms of relative price strength the Cerus share price has underperformed the S&P500 Index by -60.42% over the past year.
What are the analyst and broker recommendations for Cerus?
The overall consensus recommendation for Cerus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cerus dividend yield?
Cerus does not currently pay a dividend.
Does Cerus pay a dividend?
Cerus does not currently pay a dividend.
When does Cerus next pay dividends?
Cerus does not currently pay a dividend.
How do I buy Cerus shares?
To buy shares in Cerus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cerus?
As of the previous close price of $1.96, shares in Cerus had a market capitalisation of $348.47m.
Where are Cerus shares listed?
Here are the trading details for Cerus:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CERS
What kind of share is Cerus?
Based on an overall assessment of its quality, value and momentum Cerus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cerus share price forecast for 2023?
The analyst consensus target price for shares in Cerus is $7.75. That is 295.34% above the last closing price of $1.96.
Analysts covering Cerus currently have a consensus Earnings Per Share (EPS) forecast of -$0.22 for the next financial year.
What is the trend in the Cerus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerus. Over the past six months, its share price has underperformed the S&P500 Index by -51.51%.
As of the last closing price of $1.96, shares in Cerus were trading -41.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cerus PE Ratio?
The Cerus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cerus?
Cerus' management team is headed by:
- Daniel Swisher - NEC
- William Greenman - CEO
- Kevin Green - CFO
- Vivek Jayaraman - COO
- Carol Moore - SVP
- Laurence Corash - CSO
- Chrystal Menard - GCN
- Richard Benjamin - OTH
- Ann Lucena - DRC
- Eric Bjerkholt - IND
- Timothy Moore - IND
- Jami Nachtsheim - IND
- Gail Schulze - IND
- Frank Witney - IND